Rofecoxib

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 5, 2000, Pages 1053-1066

  Hillson, Jan L ^a   Fürst, Daniel E ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Cox 2 inhibition; NSAID

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; LACTONE; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; ROFECOXIB; SULFONE;

ANIMAL; ARTHRITIS; DRUG APPROVAL; DRUG EFFECT; HUMAN; PAIN; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG APPROVAL; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; PAIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES;

EID: 0034231459     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.5.1053     Document Type: Article

References (86)

1. LAWRENCE RC, HELMICK CG, ARNETT FC étal: Estimâtes of the prevalence of arthritis and selected nuisculoskeletal disorders in the United States. Arthritis Rheum. (1998) 41:778-799.
2. SIMON LS: Toxicities of the non-stcroidal anti-inflammatory drugs. Ctirr. Opin. Rhematol. (1992) 4:301-308.
3. MCCARTHY D: Non-steroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am.J. Med. (1998) 105(Suppl. 3A):3S-9S.
4. FOSSLIEN E: Adverse effects of non-stcroidal anti-inflammatory drugs on the gastrointestinal system. Ann. Clin. Lab. Sci. (1998) 28:67-81.
5. • •Excellent review of mechanisms and prevalence of NSAID GI toxicity.
6. LAINE L: non-stcroidal anti-inflammatory drug gastropathy. Gastrointest. Enclose. Clin. N. Am. (1996) 6:489-504.
7. FRIES JF, WILLIAMS DA, BLOCH DA et al.: NSAID associated gastropathy: incidence and risk factor models. Am.J. Med. (1991) 91:213-221.
8. FRIES JF: NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J. Rheumatol. (1991) 18(Suppl. 28):6-10
9. •Best estimate of NSAID risks based on large data-base.
10. GABRIEL SE, JAAKKIMAINEN L, BOMBARDIER C: Risks for serious gastrointestinal complications related to use of non-stcroidal anti-inflammatory drugs: a Hicta-analysis. Ann. Intern. Med. (1991) 115:787-796.
11. HAWKEY CJ: Non-steroidal anti-inflammatory drug gastropathy: causes and treatment Scan.J. Gastrocnteol. (1996) 220:124-127.
12. BLOWER AL, BROOKS A, FENN GC et al.: Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pbannacol Tber. (1997) 11:283-291.
13. LANZA FL AND THE MEMBERS OF THE AD HOC COMMITTEE ON PRACTICE PARAMETERS OF THE AMERICAN COLLEGE-OF GASTROENTEROLOGY: A guideline for the treatment and prevention of NSAIDinduced ulcers. Am. J. Gastroenterology (1998) 93:2037-2046.
14. • •Overview of risks and risk-management for NSAID GI toxicity.
15. SINGH G, RAMEY DR, MORFELD D eta!.: Gastrointestinal tract complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch. Intern. Med. (1996) 156:1530-1536.
16. SILVERSTEIN FE, GRAHAM DY, SENIOR JR et al.-. Misoprostyl reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-stcroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1995) 123:241-249.
17. JOHNSON RE, HORBROOK MC, HOOKER RS, WOODSON GT, SCHNEIDMAN R: Analysis of the costs of NSAIDassociated gastropathy. Pharmacoeconomics (1997) 12:76-88.
18. HENRY D, LIM LL-Y, RODRIGUEZ LAG eta!.: Variability in risk of gastrointestinal complications with individual non-stcroidal anti-inflammatory drugs: results of a
19. collaborative mcta-analysis. Br. Ated. J. (1996) 313:1563-1566.
20. ALLISON MC, HOWATSON AS, TORRANCE CJ et al.: Gastrointestinal damage associated with the use of NSAID. N. Engl.JMed. (1992) 327:749-754.
21. VANE JR, DOTTING RM: Biological properties of cyclooxygenase products. In: Lipid Mediators. Cunningham FM (Ed.), Academic Press, San Diego, CA, USA (1994):6l-97.
22. • Overview of the roles of prostanoids in basal and regulated processes.
23. SEMBLE EL, WU WC: Prostaglandins in the gut and their relationship to non-stcroidal anti-inflammatory drugs. Bailliere's Clin. Rhematol. (1989) 3:247-69.
24. GARELL S, MATARESE RA: Renal effects of prostaglandins and clinical adverse effects of non-stcroidal anti-inflammatory agents. Medicine (1984) 63:165-181.
25. PORTONOVA JY, ZHANG GD, ANDERSON S et al.: Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia and IL-6 production in vit'o.JExp.Mecl. (1996) 184:883-891.
26. NEEDLEMAN P, ISAKSON PC: The discovery and function of COX-2./ Rheum. (1997) 24:6-8.
27. •Review of the discovery of COX-2, its expression and function.
28. CROFFORD LJ: COX-1 and COX-2 tissue expression: implications and predictions./ Rheum. (1997) 24:15-19.
29. • •Excellent review of COX-1 and COX-2 expression, which permits prediction of drug effects.
30. SMITH G, ROBERTS R, HALL C eta!.: Reversible ovulatory failure associated with the development of lutenized unruptured follicles in tfomen with inflammatory arthritis taking non-stcroidal anti-inflammatory drugs. B.J. Rbetimatol. (1996) 35:458-462.
31. SCHMASSMANN A: Mechanisms of ulcer healing and effects of non-stcroidal anti-inflammatory drugs. Am. J. Med. (1998) 104:435-515.
32. SAIRANEN T, RISTIMAKI A, KARJALAINEN-UNDSBERG ML et al.: Cyclooxygenase is induced globally in infarcted human brain. Ann. Neiirol. (1998) 43:783-747.
33. WU KK: Biochcm Pharmacol of non-stcroidal anti-inflammatory drugs. Biocbem. Pbarmacol. (1998) 55:543-547
34. CHAN CC, BOYCE S, CHARLESON S et al: Rofecoxib: a notent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Tljer. (1999) 290:551-560.
35. • Pliarmacology of rofecoxib.
36. WARNER TD, GIULIANO F, VOJNOVIC I et al.-. Non-steroid drug selectivitics for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal activity: a full in vitro analysis. Proc. Nat!. Acad. Sci. USA (1999) 96:7563-7568.
37. • •The most complete analysis of relative inhibition of COX-1 and COX-2 by NSAIDs.
38. EHRICH EW, DALLOB A, DE LEPELEIREI etal.: Characterization of rofecoxib as a cyclooxygenase to isoform
39. inhibitor and demonstration of analgesia in the dental pain modcL Clin. Pharmacol. Ther. (1999) 65:336-347.
40. • •Efficacy data.
41. CRYER B, GOTTESDIENER K, GERTZ B et al.-. Effects of a novel cyclooxygcnase-2 inhibitor on gastric mucosal prostaglandin synthesis in healthy humans. Am. J.
42. Gastroenterol. (1996) 91:1907 #104.
43. SCHWARTZ JI, VAN HECKEN A, DE LEPELEIRE I et al: Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxcn on cox-2 vs. cox-1 in healthy female volunteers. XIV European League Against Rheumatism Congress (1999). 857.
44. MERCK AND COMPANY, INC. Vioxx prescribing information. New Jersey, USA (1999).
45. HUNT R, BOWEN B, JAMES C et ai: COX-2 specific inhibition with MK-0966 25mg or 50mg qd over 4 weeks docs not increase faecal blood loss. Am. J. Gastroetiterology (1998) 93:1671. 247.
46. • Safety data.
47. BJARNSON I, SIGTHORSSON G, CRANE R et al.: COX-2 Specific inhibition with MK-0966 25 or 50 mg qd docs not increase intestinal permeability: A controlled study with placebo (PBO) and indomethacin 50 mg t-td (INDO). Am.J. Gastroenterol. (1998) 93:1670. 246.
48. NASIR K, KHAN M, VENTUR1NI CM et al.: Interspecies differences in renal localization of cyclooxygcnase isofonns; implications in NSAIDs-related nephrotoxicity. Toxic Pathology(1998) 26(5):6l 2-620.
49. SWAN SK, LASSETER KC, RYAN CF et al.: Renal effects of multiple-dose rofecoxib, a COX-2 inhibitor in elderly patients./ Am. Soc. Nepbrol. (1999) 10(Suppl. 696):64l.
50. MURPHY MG, KiVITZ AJ & THE ROFECOXIB BONE STUDY GROUP: The effects of rofecoxib, a cyclooxygenase specific Inhibitor versus ibuprofen on biochemical indices of bone turnover in patients with ostcoarthritis. J. Bone Miner. Res. (1999) l4(Suppl.):SA134. .
51. SCHWARTZ JL, WALDMAN S, SLAUGHTER D et al.: Influence oî the selective cyclooxygenase-2 inhibitor, MK-0966 on cytochrome P450 (CYP) activity. Arch. Pbarmacol. (1998) 358(SuppI. 2):R 509. .
52. SCOTT LJ, LAMB HM: Rofecoxib. Drugs (1999) 58(3):499-505.
53. FRICKE J, MORRISON BW, FITE S et ah. MK-966 versus naproxcn sodium 550 nig in post-surgical dental pain. Am. Soc. Clin. Pharmacol. Therapeut. (1999) 65:119. PI-7.
54. MORRISON BW, CHRISTENSEN S, YUAN W et al.: Analgesic efficacy of the cyclooxygenase-2-speciflc inhibitor rofecoxib in post-dental pain: a randomized, controlled trial. Clin. Tberapeut. (1999) 21:943-953-
55. • Efficacy data.
56. MALSTROM K, DANIELS S, KOTEY P étal.: Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized,
57. placebo- and active-comparator- controlled clinical trial. Clin. Therapeut. (1999) 21:1653-1663.
58. • Efficacy data.
59. REICIN AS, BROWN J, JOVE M et al: The cox-2 specific inhibitor, rofecoxib, was effective in the treatment of postorthopedic surgical pain. Arthritis Rheiim. (1999) 42:5268. 1186.
60. SCHWARTZ JI, CHAN CG, MUKHOPADHYAY S et al.: Cycooxygenase-2 inhibition by rpfecoxib reverses naturally occurring fever in humans. Clin.Pharm. Ther. (1999) 65:653-660.
61. •Efficacy data.
62. MORRISON BW, DANIELS SE, KOTEY P et al- Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet. Gynecol. (1999) 94:504-508.
63. • Efficacy data.
64. SCHNITZER TJ, TRUITT K, FLEISCHMANN R et al.: The safety profile, tolerability and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. din. Therapeut. (1999) 21:1688-1702.
65. • Efficacy data.
66. MERCK AND CO., INC. (Mark J Greco, MD, Senior Director, Medical Services. Letter. March 27, 2000.
67. EHRICH EW, SCHNITZER TJ, MCILWAN H et at.: Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo-controlled pilot study of rofecoxib./ Rheiim. (1999) 26:2438-2447.
68. •Efficacy data.
69. EHRICH EW, SCHNITZER T, KIVITZ A et al.-. MK-966, a highly selective cox-2 inhibitor, was effective in the treatment of osteoarthritis of Jhe knee and hip in a six-week placebo-controlled study. Arthritis Rheum. (1997) 40:585. 330.
70. SAAG K, FISHER C, MCKAY J et al: MK-966, a specific cox-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis in a 6-week controlled clinical trial. Arthritis Rbettm. (1998) 4l:S196. 984.
71. GEBA GP, POLIS AB, DIXON ME et al.: Rofecoxib results in superior clinical response to nabumctonc in the treatment of osteoarthritis. Arthritis Rbeum. (1999) 42:5144. 440.
72. CANNON G, CALDWELL J, HOLT et al.: MK-0966, a specific cox-2 inhibitor, has clinical efficay comparable to diclofcnac in the treatment of knee and hip OA in a 26-week controlled clinical trial. Arthritis Rhctitn. (1998) 4l:S196. 983.
73. ACEVIDO E, ROMANOWICZ A, VAN DER HEIJDE D et al.: Rofecoxib, a cox-2 specific inhibitor, had clinical efficacy comparable to diclofcnac in the treatment of knee and hip osteoarthritis in a one-year controlled clinical trial. XIV European League Against Rheumatism Congress, 2000. 858.
74. DANIELS B, KRUPA D, EHRICH E et al.: Clinical response of OA patients who use acetaminophen when randomized to rofecoxib or ibuprofen. Arthritis Rheum. 42:5143. 436.
75. HUNT R, BOWEN B, JAMES RN et al: Cox-2 specific inhibition with MK-0966 25 or 50 mg over 4 weeks does not increase fecal blood loss: a controlled study with placebo and ibuprofen 800 mg t.i.d. Am. J. Gastment. (1998) 93:1671 247.
76. LANZA FL, RACK MF, SIMON TJ et al.: Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastrointestinal damage than cither aspirin or ibuprofen. Aliment. Pbarmacol. Ther. (1999) 13:761-767.
77. • Safety data.
78. LAINE L, HARPER S, SIMON T et al.: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-spcctfic inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with ostcoarthritis. GastrocnterologyW)y) 117:776-783.
79. • Safety data.
80. LANGMAN, MICHAEL J, DM JENSEN ET AL.: Adverse Upper Gastrointestinal effects of rofecoxib compared with KSAWs.JAMA 282:1929-1933-
81. • Overview of safety data from all studies.
82. FÜRST DE, HILLSON JL: What is the role of selective cox-2 inhibitors in the spectrum of NSAID therapy. Rheumatology Grand Rounds (1999) 1:1-10.
83. GUPTA S, MCCUNE WJ, KAPLAN MJ et al.: Thrombosis and ischemia in patients with systemic lupus erythematosis treated with celecoxib: a series of two cases. Arthritis Rheum. (1999) 42:5149 (abstract 473).
84. DE POUVOURVILLE G, TASCH RF: The economic consequences of NSAID-induccd gastrointestinal damage. Eur.J. Rheumatol. Inflamm. (1993) 13:33-40
85. KNILL-JONES RP: The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G de Pourvourvillc. Scand.J. Rheumatol. (1992) 21896:59-62.
86. KOLODNY AL, KLIPPER A: Final report on the cost of treating arthritic disease: comparison between salicyclates and non-salycilate non-steroidal anti-inflammatory drugs. Semin. Arthritis Rheum. (1985) 1481:20-24.